Long-Term Use of
acne
lipid droplet proteins
microcomedones
phytotherapy
real-life study
sebum
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
31 Dec 2022
31 Dec 2022
Historique:
received:
21
11
2022
revised:
16
12
2022
accepted:
19
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Homeostasis in the differentiation programme of sebaceous stem cells has been identified as a key step in comedogenesis and should be a target for acne-prone skin care. To report on a multicentre, year-long/real-life use study of a patented natural product containing An open-label multicentric international study, with a 12 month follow-up, included 54 teenage and young adult subjects with mild to moderate facial acne. The study was aimed at reproducing a real-life use context. Total lesion count mean was 88.3 at inclusion. There was a sustained, highly significant decrease over the months of clinical lesion counts (45.6% improvement after 6 months and 59.6% at 12 months) and on other efficacy markers, associated with a significant decrease in global microcomedone quantity on cyanoacrylate superficial skin surface biopsies. Importantly, the study protocol allowed the dermatologist to prescribe, if needed as in real life, any of the acne drugs registered in the acne guidelines. The exposure to these acne drugs during the whole year was calculated as a percentage of The association with routine prescription acne drugs when needed, even if limited, does not allow a full evaluation of the intrinsic quantitative efficacy of This open, real-life, year-long multicentre study confirms a previous 48-week proof of concept study and qualifies the use of
Sections du résumé
BACKGROUND
BACKGROUND
Homeostasis in the differentiation programme of sebaceous stem cells has been identified as a key step in comedogenesis and should be a target for acne-prone skin care.
OBJECTIVE
OBJECTIVE
To report on a multicentre, year-long/real-life use study of a patented natural product containing
METHODS
METHODS
An open-label multicentric international study, with a 12 month follow-up, included 54 teenage and young adult subjects with mild to moderate facial acne. The study was aimed at reproducing a real-life use context.
RESULTS
RESULTS
Total lesion count mean was 88.3 at inclusion. There was a sustained, highly significant decrease over the months of clinical lesion counts (45.6% improvement after 6 months and 59.6% at 12 months) and on other efficacy markers, associated with a significant decrease in global microcomedone quantity on cyanoacrylate superficial skin surface biopsies. Importantly, the study protocol allowed the dermatologist to prescribe, if needed as in real life, any of the acne drugs registered in the acne guidelines. The exposure to these acne drugs during the whole year was calculated as a percentage of
LIMITATIONS
CONCLUSIONS
The association with routine prescription acne drugs when needed, even if limited, does not allow a full evaluation of the intrinsic quantitative efficacy of
CONCLUSION
CONCLUSIONS
This open, real-life, year-long multicentre study confirms a previous 48-week proof of concept study and qualifies the use of
Identifiants
pubmed: 36675757
pii: jpm13010096
doi: 10.3390/jpm13010096
pmc: PMC9862999
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Exp Dermatol. 2020 Feb;29(2):168-176
pubmed: 31863492
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):357-364
pubmed: 31465602
J Am Acad Dermatol. 1996 Oct;35(4):559-65
pubmed: 8859284
JID Innov. 2021 Sep 17;1(4):100057
pubmed: 34909752
Clin Exp Dermatol. 1992 Jan;17(1):1-3
pubmed: 1424249
Dermatology. 2015;231(2):105-11
pubmed: 26113292
Br J Dermatol. 2019 Oct;181(4):677-690
pubmed: 31056753
Clin Cosmet Investig Dermatol. 2015 Mar 04;8:113-25
pubmed: 25767402
Nat Commun. 2020 Oct 20;11(1):5067
pubmed: 33082341
JAMA. 2021 Nov 23;326(20):2055-2067
pubmed: 34812859
J Invest Dermatol. 2017 May;137(5):e67-e71
pubmed: 28411849
J Eur Acad Dermatol Venereol. 2011 Jan;25(1):43-8
pubmed: 20456560